Freenome, Inc. (FRNM) Stock Ticker
Market factors today
Unlock the full FRNM picture
About Freenome, Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
FRNM stock facts
| Ticker symbol | FRNM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $130.4M |
| CEO | Aaron Elliott |
| Employees | 378 |
| Headquarters | Brisbane, CA, US |
| IPO date | 2026-07-21 |
| Website | www.freenome.com |
What you can see for FRNM on Tickr
Live FRNM price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the FRNM report.
Rankings
FAQ
What is the ticker symbol for Freenome, Inc.?
The ticker symbol for Freenome, Inc. is FRNM, listed on the NASDAQ.
What is FRNM?
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC…